Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial

Journal of Neuro-Oncology

Volumn 12, Issue 1, 1992, Pages 75-83

  Merchant, Randall E ^a,b   McVicar, Daniel W ^b   Merchant, Lynn H ^a   Young, Harold F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

brain tumor; cytokines; IL 2, roferon A; immunotherapy; intracavitary; toxicity

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; EDEMA; FATIGUE; FEMALE; GLIOMA; HEADACHE; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT;

ADULT; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GLIOMA; HUMAN; INJECTIONS; INJECTIONS, INTRAVENTRICULAR; INTERFERON TYPE I, RECOMBINANT; INTERLEUKIN-2; MALE; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0026570661     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/BF00172459     Document Type: Article

References (20)

1. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2
2. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor
3. Sterile abscess in glioma patients treated by intraparenchymal injection of lymphokine-activated killer (LAK) cells and recombinant interleukin-2
4. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations
5. Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas
6. Clinical use of interferons in the treatment of malignant brain tumors
7. Recombinant Interferon-alpha A (Ro 22-8181) therapy for patients with malignant brain tumors
8. Effect of human leukocyte interferon on malignant brain tumors
9. Lymphocytic infiltration in gliomas: Evidence of possible host resistance
10. Macrophages in experimental and human brain tumors. Part 2. Studies of the macrophage content of human brain tumors
11. Relationship of lymphocyte invasion and survival of brain tumor patients
12. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases
13. Immunocompetence of patients with malignant glioma
14. Depressed cell-mediated immunity in patients with primary intracranial tumors. Part 1: Studies of the cellular and humoral immune competence of brain-tumor patients
15. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours
16. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta
17. Functional analysis of interleukin-2 in immune surveillance against brain tumors
18. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects
19. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
20. Histopathologic and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin-2